Law360 Quotes William Hoffman on Lilly's Recent Cymbalta Trial Successes
Eli Lilly recently won its third straight trial over the withdrawal risks of its antidepressant Cymbalta, persuading a federal jury that warnings on the drug were adequate. Defense attorneys say this key finding gives the drugmaker an edge in an upcoming fight with plaintiffs trying to consolidate dozens of similar suits.
Litigation partner William Hoffman weighed in on Lilly's recent successes for Law360:
"From my perspective watching this litigation, this company has a strong defense that's being well-presented, that there is strong labeling for this product and that it's giving them the upper hand with judges considering summary judgment motions and at trial. That's going to weigh heavily on the JPML panel, since it has already rejected an earlier consolidation petition."
